Nutlin-3a showed robust inhibition of p53-MDM2 binding in vitro and tumor suppression with p53 upregulation in vivo, and served as a prototype in developing next-generation MDM2 inhibitors that are currently being tested in clinical trials [85]. Here, MDM2 is linked to neoplasm.